Kenji Explains on MSN

Simplify any Excel formula with LAMBDA

Learn how to use the LAMBDA function in Excel to simplify complex formulas by creating custom functions for recurring ...
pharmaphorum

Novartis' SMA gene therapy cleared for wider use in US

Novartis has a much-anticipated approval for its spinal muscular atrophy (SMA) treatment onasemnogene abeparvovec in the US, getting a green light for a new version that can make more patients ...
BBC

A simple test could have given our son a very different future

Two children with a rare genetic condition will live very different lives because one was tested at birth and the other was not, their parents say. Marley, five, and Meadow, four months, both have ...
London Evening Standard

Budget 2025 calculator: How will Rachel Reeves' statement affect you?

Today the Standard publishes a ready reckoner calculator to help readers to work out whether they will be better or worse off once all the measures announced come into effect. More than 1.7 million ...
FiercePharma

Novartis scores FDA approval for new version of SMA gene therapy, prices at $2.59M

Novartis has received an FDA approval for Itvisma, a new version of the company’s gene therapy Zolgensma, to treat older patients with spinal muscular atrophy (SMA). The approval comes more than six ...
The Star

Federal govt, Sabah begin talks on new formula to calculate 40% special grant, says Anwar

KUALA LUMPUR: The Federal Government and Sabah have begun negotiations to determine how the 40% special grant will be calculated, including the development of a new formula for the state’s future ...
The American Journal of Managed Care

FDA Approves Gene Therapy Onasemnogene Abeparvovec for Broader SMA Population

Onasemnogene abeparvovec-brve is the first gene replacement therapy approved for SMA patients aged 2 years and older, expanding access beyond infants. Phase 3 trials demonstrated significant motor ...
SMA

FDA approves SMA gene therapy Itvisma for patients 2 and older

FDA approved Itvisma, a gene therapy for SMA patients aged 2 and older. Itvisma delivers a healthy SMN1 gene via spinal injection in a one-time treatment. This expands gene therapy access to older ...
Managed Healthcare Executive

FDA approves $2.59 million gene therapy for SMA

Itvisma, a one-time gene therapy for SMA, is approved for patients aged two and older, replacing the SMN1 gene without age or weight adjustments. Priced at $2.59 million, Itvisma is more ...
BioSpace

Novartis receives FDA approval for Itvisma®, the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA)

“The FDA’s approval of intrathecal onasemnogene abeparvovec is a game-changing advance, expanding the use of transformational gene replacement therapy for SMA across age groups,” said John W. Day, MD, ...
Novartis

Novartis receives FDA approval for Itvisma®, the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA)

Itvisma (onasemnogene abeparvovec-brve) demonstrated improved motor function and stabilization in patients regardless of SMA treatment history in Phase III studies One-time dose of Itvisma replaces ...